Top 5 Health Care Stocks That May Plunge In March
Portfolio Pulse from Avi Kapoor
As of March 28, 2024, five health care stocks are considered overbought based on their RSI values, indicating potential short-term declines. These include The Pennant Group, Inc. (PNTG), Mesoblast Limited (MESO), ARS Pharmaceuticals, Inc. (SPRY), Neuronetics, Inc. (STIM), and Inozyme Pharma, Inc. (INZY). Each company has recently reported significant developments or financial results, contributing to rapid stock price increases and high RSI values.
March 28, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
INZY's stock climbed after announcing discussions on trial data, with an RSI of 71.56 indicating potential short-term volatility.
INZY's recent stock performance and RSI suggest that the stock may experience short-term volatility due to its overbought status.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 80
NEGATIVE IMPACT
MESO's stock surged after FDA feedback on its BLA submission, but a recent dip and an RSI of 71.74 suggest volatility.
MESO's recent stock performance and RSI indicate potential short-term volatility, especially after the recent price dip.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 85
NEGATIVE IMPACT
PNTG's stock has risen due to strong 2023 performance and earnings delivery, with an RSI of 90.15 indicating overbought conditions.
The significant stock price increase and high RSI value suggest that PNTG may see a short-term price correction due to its overbought status.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
SPRY's narrower Q4 loss led to a stock gain, but an RSI of 70.11 points to possible short-term pullback.
Despite the positive Q4 report, SPRY's overbought status indicated by its RSI suggests a potential short-term price correction.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
NEGATIVE IMPACT
STIM's stock rose after FDA clearance for its depression treatment, but an RSI of 72.16 signals overbought conditions.
The stock's rapid increase and high RSI value after FDA clearance suggest STIM may face a short-term price correction.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 85